雪浪环境公告，股东杨建平与许惠芬合计持有公司股份5760.24万股，占总股本的17.29%，计划在公告 披露后15个交易日内，通过集中竞价或大宗交易方式减持不超过999.43万股，即不超过公司总股本的 3%。减持原因是家庭资产规划，股份来源于公司首次公开发行前已发行的股份及因以资本公积转增股 本方式取得的股份。减持期间为3个月，减持价格区间将根据市场价格确定。此减持计划与股东此前已 披露的意向、承诺一致。 ...

证券代码：600340 证券简称：华夏幸福 公告编号：2025-043 华夏幸福基业股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东持股的基本情况 截至本公告披露日，华夏幸福基业股份有限公司 （以下简称"公司"）股 东中国平安人寿保险股份有限公司（以下简称"平安人寿"）持有公司股份 其一致行动人平安资产管理有限责任公司（以下简称"平安资管"）合计持有公 司股份 985,729,553 股，占公司目前总股本的 25.1865%。 ? 减持计划的主要内容 近日，公司收到平安资管致送的《持股 5%以上股东股份减持计划告知函》， 平安人寿与平安资管计划自本公告披露之日起 15 个交易日后的 3 个月内，拟减 持所持股份不超过 117,411,610 股，占公司总股本比例不超过 3%。其中，拟通 过大宗交易方式进行减持的，在任意连续 90 日内减持股份数量不超过公司总股 本的 2%；拟通过集中竞价交易方式进行减持的，在任意连续 90 日内减持股份数 量不 ...

证券代码：688210 证券简称：统联精密 公告编号：2025-052 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 控股股东、实际控制人持股的基本情况 截至本公告披露日，深圳市泛海统联精密制造股份有限公司（以下简称"公 司"或"发行人"）控股股东、实际控制人杨虎先生直接持有公司无限售流通股 份 34,909,595 股，占公司总股本的 21.79%，所持股份为其在公司 IPO 之前取得 的股份（含上市以来资本公积转增股本取得的股份）、集中竞价交易增持取得的 股份以及股权激励取得的股份；深圳市泛海统联科技企业（有限合伙）（以下简 称"泛海统联（合伙）"）持有公司无限售流通股份 8,557,711 股，占公司总股本 的 5.34%，所持股份为其在公司 IPO 之前取得的股份（含上市以来资本公积转增 股本取得的股份）。上述股东在公司 IPO 之前取得的股份（含上市以来资本公积 转增股本取得的股份）已于 2025 年 6 月 27 日起解除限售并上市流通。 ? 减持计划的主要内容 杨虎先生拟减持 ...

Core Viewpoint - The company Juguang Technology (688167.SH) announced that several shareholders plan to reduce their holdings by a total of up to 1,882,581 shares, representing no more than 2.0950% of the company's total share capital, due to personal funding needs [1] Summary by Relevant Categories Shareholder Actions - Shareholders including Song Tao, Yan Suibin, Li Xiaoning, Tian Ye, Ningbo Ningju, Ningbo Xinjun, and Ningbo Jichen intend to reduce their stakes through centralized bidding and block trading [1] - The reduction period is set from September 1, 2025, to November 30, 2025 [1] Shareholding Background - All mentioned shareholders acquired their shares before the company's IPO [1]

Group 1 - The company, Beijing New Space Technology Co., Ltd., has announced a share buyback plan, approved by the board and shareholders, to repurchase shares using between RMB 3 million and RMB 5 million within a specified period [2][3] - The buyback will occur from July 18, 2025, to August 15, 2025, at a price not exceeding RMB 27.72 per share, with all repurchased shares to be canceled and the registered capital reduced [2][3] - As of August 7, 2025, the company has repurchased 165,600 shares, representing 0.17% of the total share capital, at a maximum price of RMB 23.13 per share and a minimum price of RMB 22.77 per share, totaling RMB 380.88 million [3][4] Group 2 - On August 7, 2025, the company received a notification from shareholder Zhou Lei regarding a reduction in shareholding, having sold 806,800 shares, which is 0.81% of the total share capital, decreasing her ownership from 4.80% to 3.99% [8][9] - This reduction is part of a previously disclosed share reduction plan and does not trigger a mandatory tender offer or change the controlling shareholder [8][9] - The company will continue to monitor compliance with relevant regulations regarding share reductions and ensure timely information disclosure [9][10]

共创草坪（605099）(605099.SH)发布公告，创享投资、王强众拟通过上海证券交易所交易系统以集中 竞价、大宗交易的方式分别减持股份不超过148.5万股和172.7万股，即各自减持股份不超过公司股份总 数的0.37%和0.43%。 ...

Core Viewpoint - Zhongsheng Pharmaceutical's stock price has experienced a decline, and the company is planning a share reduction by its financial director while also projecting significant profit growth for the first half of 2025 [1] Company Summary - As of August 6, 2025, Zhongsheng Pharmaceutical's stock price is reported at 20.05 yuan, down 0.75 yuan or 3.61% from the previous trading day [1] - The company operates in the pharmaceutical manufacturing industry, specifically within the traditional Chinese medicine sector, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, raw materials, and health products [1] - Zhongsheng Pharmaceutical has a diverse product line that addresses various therapeutic areas, including cardiovascular, respiratory, and digestive systems [1] Financial Summary - The company announced that its Vice President and CFO, Long Chunhua, plans to reduce holdings by up to 900,000 shares within the next three months, which is estimated to be around 18 million yuan based on the current stock price [1] - A performance forecast released on July 15 indicates that the net profit for the first half of 2025 is expected to be between 170 million yuan and 210 million yuan, representing a year-on-year growth of 94.49% to 140.25% [1] - On August 6, the net outflow of main funds for Zhongsheng Pharmaceutical was 149.61 million yuan, accounting for 0.98% of the circulating market value, while the cumulative net inflow over the past five trading days was 282.37 million yuan, representing 1.85% of the circulating market value [1]

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Shanghai Haoyuan Pharmaceutical Co., Ltd., driven by the shareholder's personal funding needs, which may impact the company's stock performance and investor sentiment [2][3]. Shareholder Holding Situation - Prior to the reduction plan, the shareholder, Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), held 6,909,364 shares, accounting for 3.26% of the company's total share capital [2]. Reduction Plan Details - The shareholder plans to reduce holdings by up to 6,362,959 shares, representing no more than 3% of the total share capital. This includes a maximum of 2,120,986 shares through centralized bidding (up to 1% of total shares) and 4,241,973 shares through block trading (up to 2% of total shares) [3][4]. - The reduction will occur within three months following a 15 trading day period after the announcement [3]. Shareholder's Past Reduction Activity - The shareholder has previously reduced shares, with details available in earlier announcements from February and June 2025 [6]. Shareholder Commitments - The shareholder has made commitments regarding share lock-up and reduction intentions, including a 12-month lock-up period post-IPO and adherence to legal regulations for any future reductions [9][10].

民德电子(300656.SZ)发布公告，公司控股股东、实际控制人许香灿及公司董事、副总经理易仰卿计划 在未来三个月内，以大宗交易或集中竞价方式减持公司股份，减持数量均不超过339.83万股，即不超过 剔除公司回购专用账户股份数量后总股本的2%。减持期间为自公告之日起十五个交易日后的三个月 内。 ...

晶升股份公告，股东鑫瑞集诚（厦门）创业投资合伙企业（有限合伙）持有股份1701.84万股，占总股 本12.30%，与一致行动人吴亚宏合计持股12.66%。因自身资金需求，鑫瑞集诚计划自2025年8月29日至 2025年11月28日，通过集中竞价减持不超138.36万股（不超1%）及大宗交易减持不超276.73万股（不超 2%），合计减持不超过415.09万股，减持比例不超过3%。减持价格不得低于31.82元/股。 ...